FDA Approves KALYDECO™ (ivacaftor) ... to Treat the Underlying Cause of Cystic Fibrosis

FDA Approves KALYDECO™ (ivacaftor) ... to Treat the Underlying Cause of Cystic Fibrosis

Fred Van Goor, Ph.D., Head of Biology, CF Research Program, Vertex, discussing the path to KALYDECO discovery and development. www.businesswire.com
Video Rating: 0 / 5

Explains the prevention, causes, symptoms, modes of transmission, and treatment of hepatitis C.

---

Orignal From: FDA Approves KALYDECO™ (ivacaftor) ... to Treat the Underlying Cause of Cystic Fibrosis